CERNOSTICS, INC.
FRIENDSWOOD, TX

Cernostics, Inc., founded on August 29, 2016, is a forward-thinking diagnostics company based in Friendswood, Texas. With its innovative TissueCypher™ platform, the firm specializes in next-generation cancer diagnostics and prognostics through advanced tissue analysis using genomic and proteomic approaches. Under the leadership of Mike Hoerres, CEO with over three decades of experience in life sciences, Cernostics leverages strategic market-building insights gained from his time as a Principal at Geisinger Ventures to enhance healthcare outcomes. Collaborations with established partners like Geisinger Health System are pivotal to their mission of advancing personalized medicine. Dr. Critchley-Thorne leads the R&D department, bringing expertise in cancer immunology and molecular profiling, honed during her collaborative work on breast cancer diagnostics at Mayo Clinic. Her efforts, along with those of Noel Doheny-who contributes invaluable knowledge from his global diagnostic market experience-underscore Cernostics' commitment to ground-breaking innovation. The company's leadership team benefits from the strategic acumen of Courtland Longest, an industry expert who directs precision medicine projects at UPMC Enterprises and offers guidance as a board member at Cernostics. Together, their combined expertise drives advancements in oncology diagnostics, addressing crucial unmet needs within the field. As an actively registered Florida corporation, Cernostics continues to broaden its impact with strategic operations rooted in Friendswood, Texas. The company remains accessible to those interested in precision diagnostics by phone or online through their website.